Management of patients with resistant hypertension: current treatment options
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Resistant hypertension (RHTN) is an increasingly common clinical problem that is often heterogeneous in etiology, risk factors, and comorbidities. It is defined as uncontrolled blood pressure on optimal doses of three antihypertensive agents, ideally one being a diuretic. The definition also includes controlled hypertension with use of four or more antihypertensive agents. Recent observational studies have advanced the characterization of patients with RHTN. Patients with RHTN have higher rates of cardiovascular events and mortality compared with patients with more easily controlled hypertension. Secondary causes of hypertension, including obstructive sleep apnea, primary aldosteronism, renovascular disease, are common in patients with RHTN and often coexist in the same patient. In addition, RHTN is often complicated by metabolic abnormalities. Patients with RHTN require a thorough evaluation to confirm the diagnosis and optimize treatment, which typically includes a combination of lifestyle adjustments, and pharmacologic and interventional treatment. Combination therapy including a diuretic, a long-acting calcium channel blocker, an angiotensin-converting enzyme inhibitor, a beta blocker, and a mineralocorticoid receptor antagonist where warranted is the classic regimen for patients with treatment-resistant hypertension. Mineralocorticoid receptor antagonists like spironolactone or eplerenone have been shown to be efficacious in patients with RHTN, heart failure, chronic kidney disease, and primary aldosteronism. Novel interventional therapies, including baroreflex activation and renal denervation, have shown that both of these methods may be used to lower blood pressure safely, thereby providing exciting and promising new options to treat RHTN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marin, J. M., Carrizo, S. J., Vicente, E., & Agusti, A. G. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71141-7 · Cited by 4,678
Sympathetic neural mechanisms in obstructive sleep apnea.
Somers, V. K., Dyken, M. E., Clary, M. P., & Abboud, F. M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118235 · Cited by 2,527
Krum, H., Schlaich, M., Whitbourn, R., Sobotka, P. A., Sadowski, J., Bartus, K., Kapelak, B., Walton, A., Sievert, H., Thambar, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60566-3 · Cited by 2,108
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
Jamerson, K., Weber, M. A., Bakris, G. L., Dahlöf, B., Pitt, B., Shi, V., Hester, A., Gupte, J., Gatlin, M., & Velazquez, E. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806182 · Cited by 2,065 · cited 1×
“In the more recent ACCOMPLISH (Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension) study, 25%–28% of subjects remained uncontrolled during the course of the study in spite of intensification of treatment.(7)”
Effect of Aerobic Exercise on Blood Pressure: A Meta-Analysis of Randomized, Controlled Trials
Whelton, S. P., Chin, A., Xin, X., & He, J. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-7-200204020-00006 · Cited by 1,970
The sympathetic control of blood pressure
Guyenet, P. G. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1902 · Cited by 1,863 · cited 1×
“Novel device therapies for resistant hypertension Baroreflex activation therapy with carotid stimulation There is an increasing body of research that implicates the carotid baroreceptors as being activated by pressure that leads to compensatory adjustments in the sympathetic and parasympathetic nervous system involved…”
High prevalence of unrecognized sleep apnoea in drug-resistant hypertension
Logan, A. G., Perlikowski, S. M., Mente, A., Tisler, A., Tkacova, R., Niroumand, M., Leung, R. S. T., & Bradley, T. D. (2001) · Journal of Hypertension · doi:10.1097/00004872-200112000-00022 · Cited by 960 · cited 15×
“Recently, a large, retrospective cohort study described use of antihypertensive agents in patients with RHTN. 71 The most frequently prescribed antihypertensive classes were an ACE inhibitor and/or ARB in 96.2%, a diuretic in 93.2%, a calcium channel blocker in 83.6%, and a beta-blocker in 80.0% of patients.”
InfluentialIncidence and Prognosis of Resistant Hypertension in Hypertensive Patients
Daugherty, S. L., Powers, J. D., Magid, D. J., Tavel, H. M., Masoudi, F. A., Margolis, K. L., O'Connor, P. J., Selby, J. V., & Ho, P. M. (2012) · Circulation · doi:10.1161/circulationaha.111.068064 · Cited by 930
de la Sierra, A., Segura, J., Banegas, J. R., Gorostidi, M., de la Cruz, J. J., Armario, P., Oliveras, A., & Ruilope, L. M. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.168948 · Cited by 809
Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension
Schlaich, M. P., Sobotka, P. A., Krum, H., Lambert, E., & Esler, M. D. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0904179 · Cited by 772 · cited 1×
“Cardiac magnetic resonance imaging 12 months after the procedure showed a decrease in left ventricular mass of 9%.(97) A follow-up study at 24 months of SYMPLICITY HTN-1 showed a BP reduction of 32/14 mmHg, thus demonstrating the long-term antihypertensive effect of RDN.”
Baroreflex Activation Therapy Lowers Blood Pressure in Patients With Resistant Hypertension
Bisognano, J. D., Bakris, G., Nadim, M. K., Sanchez, L., Kroon, A. A., Schafer, J., de Leeuw, P. W., & Sica, D. A. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.008 · Cited by 600 · cited 11×
“In this double-blind, randomized, placebo-controlled trial that enrolled 322 subjects with RHTN, 93 the Rheos device was implanted in 265 subjects who were subsequently randomized to immediate baroreflex activation therapy for the first 6 months or deferred baroreflex activation therapy after 6 months.”
InfluentialUncontrolled and Apparent Treatment Resistant Hypertension in the United States, 1988 to 2008
Egan, B. M., Zhao, Y., Axon, R. N., Brzezinski, W. A., & Ferdinand, K. C. (2011) · Circulation · doi:10.1161/circulationaha.111.030189 · Cited by 599
Pimenta, E., Gaddam, K. K., Oparil, S., Aban, I., Husain, S., Dell'Italia, L. J., & Calhoun, D. A. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.131235 · Cited by 531
Ernst, M. E., Carter, B. L., Goerdt, C. J., Steffensmeier, J. J. G., Phillips, B. B., Zimmerman, M. B., & Bergus, G. R. (2006) · Hypertension · doi:10.1161/01.hyp.0000203309.07140.d3 · Cited by 433
Anderson, G. H., Blakeman, N., & Streeten, D. H. P. (1994) · Journal of Hypertension · doi:10.1097/00004872-199405000-00015 · Cited by 403
Aerobic Exercise Reduces Blood Pressure in Resistant Hypertension
Dimeo, F., Pagonas, N., Seibert, F., Arndt, R., Zidek, W., & Westhoff, T. H. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.197780 · Cited by 370
Kokkinos, P. F., Narayan, P., Colleran, J. A., Pittaras, A., Notargiacomo, A., Reda, D., & Papademetriou, V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332204 · Cited by 354 · cited 1×
“In a small group of African American men with RHTN, 16 weeks of stationary cycling three times a week reduced BP by 7/5 mmHg.(69) Reductions in diastolic BP were maintained after 32 weeks of exercise, even with withdrawal of some antihypertensive medications.”
Pratt-Ubunama, M. N., Nishizaka, M. K., Boedefeld, R. L., Cofield, S. S., Harding, S. M., & Calhoun, D. A. (2007) · Chest · doi:10.1378/chest.06-1442 · Cited by 331 · cited 1×
“Recent studies indicate that obstructive sleep apnea is significantly associated with increased aldosterone excretion(12) and there seems to be a significant correlation between aldosterone levels and the severity of obstructive sleep apnea.(15) It is hypothesized that chronic parapharyngeal fluid retention, mediated…”
Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled
BRAMLAGE, P., PITTROW, D., WITTCHEN, H., KIRCH, W., BOEHLER, S., LEHNERT, H., HOEFLER, M., UNGER, T., & SHARMA, A. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.05.017 · Cited by 328 · cited 1×
“weight loss Obesity has been shown to be associated with RHTN and an increased number of antihypertensive agents.(66) Consistent with this observation, weight loss studies have been shown to be effective in BP-lowering.”
Gallay, B. J., Ahmad, S., Xu, L., Toivola, B., & Davidson, R. C. (2001) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(01)80117-7 · Cited by 304
Gaddam, K., Pimenta, E., Thomas, S. J., Cofield, S. S., Oparil, S., Harding, S. M., & Calhoun, D. A. (2010) · Journal of Human Hypertension · doi:10.1038/jhh.2009.96 · Cited by 289 · cited 1×
“The hypothesis of aldosterone excess worsening severity of obstructive sleep apnea is supported by a prospective study showing a reduction in severity after 8 weeks of treatment with spironolactone in patients with RHTN and obstructive sleep apnea.(19)”
Low-renin status in therapy-resistant hypertension: a clue to efficient treatment
Eide, I. K., Torjesen, P. A., Drolsum, A., Babovic, A., & Lilledahl, N. P. (2004) · Journal of Hypertension · doi:10.1097/00004872-200411000-00026 · Cited by 265 · cited 1×
“26 28 A prominent role of aldosterone excess as a cause of treatment resistance is supported by numerous studies that demonstrate a significant antihypertensive effect when mineralocorticoid receptor antagonists are added, as outlined later in this review.”
Aldosterone Excretion Among Subjects With Resistant Hypertension and Symptoms of Sleep Apnea
Calhoun, D. A., Nishizaka, M. K., Zaman, M. A., & Harding, S. M. (2004) · Chest · doi:10.1378/chest.125.1.112 · Cited by 260 · cited 17×
“Recently, a large, retrospective cohort study described use of antihypertensive agents in patients with RHTN. 71 The most frequently prescribed antihypertensive classes were an ACE inhibitor and/or ARB in 96.2%, a diuretic in 93.2%, a calcium channel blocker in 83.6%, and a beta-blocker in 80.0% of patients.”
InfluentialAucott, L., Poobalan, A., Smith, W. C. S., Avenell, A., Jung, R., & Broom, J. (2005) · Hypertension · doi:10.1161/01.hyp.0000165680.59733.d4 · Cited by 241
Štrauch, B., Zelinka, T., Hampf, M., Bernhardt, R., & Widimsky, J. (2003) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001554 · Cited by 237
Efficacy of Spironolactone Therapy in Patients With True Resistant Hypertension
de Souza, F., Muxfeldt, E., Fiszman, R., & Salles, G. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.140988 · Cited by 234
Flash pulmonary oedema and bilateral renal artery stenosis: the Pickering Syndrome
Messerli, F. H., Bangalore, S., Makani, H., Rimoldi, S. F., Allemann, Y., White, C. J., Textor, S., & Sleight, P. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr056 · Cited by 183
Pimenta, E., Stowasser, M., Gordon, R. D., Harding, S. M., Batlouni, M., Zhang, B., Oparil, S., & Calhoun, D. A. (2013) · Chest · doi:10.1378/chest.12-0802 · Cited by 69 · cited 1×
“with RHTN, a low-sodium diet was compared with a high-salt diet.(63) Twelve subjects with resistant hypertension entered into a randomized crossover evaluation of low (50 mmol/24 hours × 7 days) and high (250 mmol/24 hours × 7 days) sodium diets, separated by a 2-week washout period.”
Cited by
Adherence in Hypertension: A Review of Prevalence, Risk Factors, Impact, and Management
Burnier, M., & Egan, B. M. (2019) · Circulation Research · doi:10.1161/circresaha.118.313220 · Cited by 878
A content analysis of smartphone–based applications for hypertension management
Kumar, N., Khunger, M., Gupta, A., & Garg, N. (2015) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.12.001 · Cited by 208
Self-citationResistant hypertension: an approach to management in primary care
Yaxley, J., & Thambar, S. (2015) · Journal of Family Medicine and Primary Care · doi:10.4103/2249-4863.154630 · Cited by 70
Metadata
- Authors
- Dudenbostel, T., Kumar, N., & Calhoun
- Venue
- Integrated Blood Pressure Control
- Publisher
- Informa UK Limited
- Published
- 2013-10
- Volume
- 6
- Pages
- 139
- ISSN
- 1178-7104 (ISSN-L)
- OpenAlex
- W2069299400
- Cited by
- 36
- References
- 28
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.